Acrotech Biopharma Inc.

Biotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

Feb 12, 2026FDAAdquey — ADQUEY

Oct 4, 2023TrialTo Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Dec 28, 2022TrialStudy to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

Oct 1, 2022TrialThis Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Sep 15, 2022TrialA Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Aug 15, 2020TrialPK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients

Aug 5, 2019TrialExtension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

4 patent groups across drugs · Source: FDA Orange Book

DrugExpires

BeleodaqAug 10, 2026 BeleodaqOct 27, 2027 AdqueyMar 1, 2028 AdqueyDec 31, 2036

Regulatory

Regulatory Timeline

20021 event

FDAFeb 19

ZEVALIN — ZEVALIN

Application BLA125019 (BLA)

20091 event

FDASep 24

Folotyn — FOLOTYN

Application NDA022468 (NDA)

20141 event

FDAJul 3

Beleodaq — BELEODAQ

Application NDA206256 (NDA)

20261 event

FDAFeb 12

Adquey — ADQUEY

Application NDA219474 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)